A Study of the Improvement of Symptoms in GERD Patients by Practical Use of Esomeprazole 20mg

A Study of the Improvement of Symptoms in GERD Patients by Practical Use of Esomeprazole 20mg - A Study of the Improvement of Symptoms in GERD Patients by Practical Use of Esomeprazole 20mg

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018456

Enrollment

Registered

2015-07-28

Start date

2011-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesohageal reflux disease

Interventions

Esomeprazole20mg/day for 4 weeks p.o.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible, enrolled patients were who had judged to be appropriate to start the treatment of PPIs defined by GerdQ questionnaire and who had judged having insufficient therapeutic effects also defined by GerdQ despite continuing the conventional PPIs for four weeks or more.

Exclusion criteria

Exclusion criteria: The patient that a serious heart, liver, renal function disorder, a patient developing a malignant neoplasm, a gastrointestinal tract resection, stomach esophagus junction rebuilding art, a patient having the past of the straying neurolysis, the combination taboo medicine of esomeprazole

Design outcomes

Primary

Measure	Time frame
Treatment reactivity by GerdQ after Esomepurazole20 mg administration 4 weeks	—

Secondary

Measure	Time frame
Reflux symptom disapearance by GERDQ and Frequency Scale for the symptom of GERD (FSSG) and acid reflux related conditions score by FSSG	—

Countries

Japan

Contacts

Public ContactIshihara shinichi

Ishihara Gastroenterology clini Internalmedicine

ccy63890@yahoo.co.jp0877-63-6677

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026